Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584559 | 1.00 | APP (0.48) | APPATMHCAR2MAOBMAPT | |
| SCHEMBL1567688 | 0.81 | APP (0.47) | APPATMHCAR2MAOBMAPT | |
| SCHEMBL1567687 | 0.81 | APP (0.47) | APPATMHCAR2MAOBMAPT | |
| SCHEMBL585756 | 0.81 | ALOX5 (0.50) | APPATMHCAR2ALOX5HPGD | |
| SCHEMBL585757 | 0.81 | ALOX5 (0.50) | APPATMHCAR2ALOX5HPGD | |
| SCHEMBL6792876 | 0.79 | APP (0.53) | APPATMHCAR2MAPTRAB9A | |
| SCHEMBL6792878 | 0.79 | APP (0.53) | APPATMHCAR2MAPTRAB9A | |
| SCHEMBL584880 | 0.78 | APP (0.55) | APPATMHCAR2ALOX5HPGD | |
| SCHEMBL584879 | 0.78 | APP (0.55) | APPATMHCAR2ALOX5HPGD | |
| SCHEMBL8942198 | 0.76 | APP (0.50) | APPATMHCAR2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188082-B2 | 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-29 | — | — | US | disclosed |
| EP-2125823-B1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2125823-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008078291-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | HCRTR1, HCRTR2, NPY5R | APP 1433/4885ATM 4876/4885HCAR2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.